Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expressionjog

Journal of Obstetrics and Gynaecology Research

Volumn 38, Issue 8, 2012, Pages 1077-1085

  Dong, Lingling ^a,b   Zhou, Qian ^b   Zhang, Zhenbo ^c   Zhu, Yaping ^c   Duan, Tao ^b   Feng, Youji ^c  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chemotherapy; Endometrial cancer; GloI; Metformin; Proliferation

Indexed keywords

CISPLATIN; LACTOYLGLUTATHIONE LYASE; METFORMIN; PACLITAXEL;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL KILLING; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; SENSITIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOGLYCEMIC AGENTS; LACTOYLGLUTATHIONE LYASE; METFORMIN; PACLITAXEL;

EID: 84864619407     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2011.01839.x     Document Type: Article

References (25)

1. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-649.
2. Pagel J, Bock JE. Endometrial cancer. A review. Dan Med Bull 1984; 31: 333-345.
3. Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 2009; 16: 363-380.
4. Nordstrom B, Strang P, Lindgren A et al. Endometrial carcinoma: The prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res 1996; 16: 899-904.
5. Jiang T, Chen N, Zhao F et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010; 70: 5486-5496.
6. Hahn HS, Yoon SG, Hong JS et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009; 19: 1068-1073.
7. Zivanovic O, Carter J, Kauff ND et al. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 2009; 115: 504-509.
8. Benshushan A. Endometrial adenocarcinoma in young patients: Evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol 2004; 117: 132-137.
9. Kaku T, Yoshikawa H, Tsuda H et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: Central pathologic review and treatment outcome. Cancer Lett 2001; 167: 39-48.
10. Hirsch HA, Iliopoulos D, Tsichlis PN et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507-7511.
11. Zhang Z, Dong L, Sui L et al. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer 2011; 21: 213-221.
12. Saltzman BS, Doherty JA, Hill DA et al. Diabetes and endometrial cancer: An evaluation of the modifying effects of other known risk factors. Am J Epidemiol 2008; 167: 607-614.
13. Lucenteforte E, Bosetti C, Talamini R et al. Diabetes and endometrial cancer: Effect modification by body weight, physical activity and hypertension. Br J Cancer 2007; 97: 995-998.
14. Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
15. Antognelli C, Baldracchini F, Talesa VN et al. Overexpression of glyoxalase system enzymes in human kidney tumor. Cancer J 2006; 12: 222-228.
16. Sakamoto H, Mashima T, Kizaki A et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000; 95: 3214-3218.
17. Davies GF, Roesler WJ, Juurlink BH et al. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma 2005; 46: 1199-1206.
18. Sakamoto H, Mashima T, Sato S et al. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 2001; 7: 2513-2518.
19. Sui L, Guo QS, Zhang ZB et al. [Expression of glyoxalase I and its effect on cell proliferation and apoptosis in endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2010; 45: 429-433.
20. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
21. Zhang Z, Jia L, Feng Y et al. Overexpression of folliclestimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett 2009; 278: 56-64.
22. Shechter-Maor G, Bruchim I, Ben-Harim Z et al. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer. Int J Gynecol Cancer 2009; 19: 662-664.
23. Cantrell LA, Zhou C, Mendivil A et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010; 116: 92-98.
24. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008; 112: 465-467.
25. Session DR, Kalli KR, Tummon IS et al. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol 2003; 17: 405-407.